Indian Pharmaceutical Industry

Indian Pharmaceutical Industry

The purpose of this TriMark Publications study is to describe the specific segment of the pharmaceutical market sector called the Indian pharmaceutical industry. This sector includes all of the generally-accepted pharmaceutical manufacturing activities that are currently used today, including the bulk drug industry, formulations and major therapeutic segments. It examines these clinical supplies as utilized in hospitals, clinics and doctor’s offices. The principal objectives of this analysis are to: 1) identify viable technology drivers through a comprehensive look at various platform technologies for the Indian pharmaceutical industry; 2) obtain a complete understanding of the Indian pharmaceutical industry practices from its basic principles to its applications; 3) discover feasible market opportunities via an identification of high-growth applications in different areas of the Indian pharmaceutical industry, with a focus on the biggest and expanding markets for the Indian pharmaceutical industry; 4) focus on global industry development through an in-depth analysis of the major world markets for pharmaceutical manufacturing, including forecasts for growth; and 5) establish the essentials of the Indian pharmaceutical market including definitions, processes and trends.

4.3.1 Bulk Drug Industry

4.3.1.1 Production and Exports of Drugs and Pharmaceuticals

4.3.1.2 Projections for Bulk Drugs and Formulations—1997-98 to 2001-02

4.3.2 Formulations

5.1.1 Glaxo

5.1.1.1 Performance Summary

5.1.1.2 Performance Drivers in 2004

5.1.2 Pfizer India

5.1.2.1 Performance Summary

5.1.2.2 Performance Drivers in 2005

5.1.2.3 Analyst Expectations

5.1.3 Aventis Pharma

5.1.3.1 Performance Summary

5.1.3.2 Performance Drivers in 2QCY04

5.1.3.3 Analyst Forecast

5.1.4 Novartis India

5.1.4.1 Performance Summary

5.1.4.2 Performance Drivers in 3QFY05

5.1.4.3 Analyst Expectations

5.2.1 Ranbaxy

5.2.1.1 Analyses

5.2.1.2 Performance Drivers in 2004

5.2.2 Dr. Reddy’s Labs (DRL)

5.2.2.1 Performance Summary

5.2.2.2 Performance Drivers

5.2.3 Cipla

5.2.3.1 Performance Summary

5.2.3.2 Performance Drivers in 3QFY05

5.2.4 Sun Pharma

5.2.4.1 Performance Summary

5.2.4.2 Performance Drivers in 2QFY05

5.2.4.3 Analyst Expectations

5.2.5 Abbott India Limited (Knol)

5.2.6 Wockhardt

5.2.6.1 Performance Summary

5.2.6.2 Peformance Drivers in 2004

5.2.7 Nicholas Piramal India

5.2.8 Lupin

7.6.1 New Product Launches

7.6.2 Therapeutic Coverage

7.6.3 Sales and Distribution Network

7.6.4 Strong Brands

7.6.5 Exports

7.6.6 Critical Mass

7.7.1 Low Cost Structure

7.7.2 Internationally Approved Manufacturing Facilities

7.7.3 Speedy Launches

7.8.1 Basic R&D

7.8.2 Applied Research and Development

7.8.3 Process Research or Reverse Engineering

7.8.4 Analogue or Discovery Research

7.9.1 Biotech, Bio-Generics and Vaccines

7.9.2 Cost Advantage of Indian Biotech Industry

7.9.3 Challenges Facing the Indian Bio-Generics

7.9.4 Vaccine Manufacturing

7.9.5 Vaccine R&D

10.4.1 On Prices of Drugs

10.4.2 On R&D

12.2.1 State Pharmacy Councils

12.2.2 Registration of Pharmacists

12.4.1 State Pharmacy Councils

12.4.2 Registration of Pharmacists

16.1.1 Budget Proposals 2005-06

22.5.1 1970 to Early 1980s

22.5.2 Early 1980s to 1994

22.5.3 1994 to 1997

22.5.4 1997 Onwards

23.2.1 Growth through Mergers and Acquisitions

23.2.2 Growth through Brand Acquisition

23.2.3 Growth through Licensing Agreements

7.1.1 Systemic Toxicity Studies

7.1.1.1 Single-dose Toxicity Studies

7.1.1.2 Repeated-dose Systemic Toxicity Studies

7.1.2 Male Fertility Study

7.1.3 Female Reproduction and Developmental Toxicity Studies

7.1.3.1 Female Fertility Study (Segment I)

7.1.3.2 Teratogenicity Study (Segment II)

7.1.3.3 Perinatal Study (Segment III)

7.1.4 Local toxicity

7.1.5 Allergenicity/Hypersensitivity

7.1.6 Genotoxicity

7.1.7 Carcinogenicity

9.1.1 Specific Pharmacological Actions

9.1.2 General Pharmacological Actions

9.1.2.1 Essential Safety Pharmacology

9.1.3 Follow-up and Supplemental Safety Pharmacology Studies

9.1.3.1 Follow-up Studies for Essential Safety Pharmacology

9.1.3.2 Supplemental Safety Pharmacology Studies

9.1.4 Conditions under Which Safety Pharmacology Studies are not Necessary

9.1.5 Timing of Safety Pharmacology Studies in Relation to Clinical Development

9.1.5.1 Prior to First Administration in Humans

9.1.5.2 During Clinical Development

9.1.5.3 Before Applying for Marketing Approval

9.1.6 Application of Good Laboratory Practices (GLP)

10.1.1 Essential Elements

10.1.2 Additional Elements, which may be Required